2 citations,
October 2022 in “Current Dermatology Reports” People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.
February 2024 in “BMJ Open” The study concluded that different treatments reduced post-COVID symptoms over time and that factors like age, severity, and comorbidities affect symptom risk.
October 2023 in “Microorganisms” Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
84 citations,
March 2010 in “Infectious Disease Clinics of North America” The document concludes that rapid identification, isolation, and strict infection control are crucial to manage SARS outbreaks.
52 citations,
September 2021 in “Kidney International” COVID-19 vaccination may trigger lupus in some people.